
Convelo Therapeutics: Innovating myelin regeneration treatments via stem cell stimulation.
Convelo Therapeutics, founded with the mission to revolutionize treatments for neurological disorders, focuses on developing medicines that regenerate myelin around nerve cells. Their core vision is to restore neurological function by leveraging an innovative platform that identifies novel candidate treatments. These treatments aim to directly stimulate stem cells in the central nervous system to form new myelin, addressing conditions like Multiple Sclerosis.
Notable figures affiliated with Convelo Therapeutics include leading scientists and executives in the field of neurology and regenerative medicine. The company has garnered significant attention and investment due to its groundbreaking approach and potential impact on treating demyelinating diseases. Convelo's key achievements include the development of a proprietary platform for remyelination, positioning them as a pioneering force in neurological therapeutics.

Convalesce
convalesce.co

Novoron Bioscience
novoron.com

Bolden Therapeutics

Myrobalan Therapeutics
myrotx.com

Pipeline Therapeutics

Celvive

Convoy Therapeutics

Autobahn Therapeutics
autobahntx.com

NeuExcell Therapeutics
neuexcell.com

Regennova
regennova.com

Neurona Therapeutics

ReNetX Bio
renetx.com

Stemson Therapeutics
stemsontx.com

Convergent Therapeutics
convergentrx.com

Cell Reprogramming & Therapeutics
Companies similar to Convelo Therapeutics include Convalesce, Novoron Bioscience, Bolden Therapeutics and Myrobalan Therapeutics.
Convelo Therapeutics was founded in 2016.
Convelo Therapeutics' headquarters is located in Cleveland, OH, US.
Convelo Therapeutics' most recent funding round was for $10.8M (USD) in December 2022.
As of Dec 8, 2022, Convelo Therapeutics has raised a total of $20.6M (USD).
Convelo Therapeutics has 18 employees as of Feb 5, 2024.